arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

PUMA BIOTECHNOLOGY, INC.

PBYI
$8.95 ▲ +0.81 (+9.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
70 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

PUMA BIOTECHNOLOGY, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $455.1M
Dividend Yield
Revenue Growth -2.6%
Op. Margin -8.5%
ROIC -2.2%
FCF / Share $0.30
Trailing P/E
Price / Book 3.6x
FCF Yield 3.4%
Debt / Equity 0.09
info Valuation on last close. End-of-day price, Aug 7, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.81M
↓ -2.6%
Net Income Profit after all expenses
$-3.75M
↓ -127.9%
Operating Margin Operating profit as % of sales
-8.5%
↓ -137.7% 69th
FCF / Share Free cash flow per share
$0.30
↑ +323.5%
Long-Term Debt Long-term obligations
$11.34M
↓ -50.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
74
Returns
90
Financial Health
76
Cash Quality
77

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 70 quarters